Tag Archives: Industry Analysis

IPO Update – November 11th, 2010

Today’s IPO from Complete Genomics (GNOM) brings the US biotech IPO list to 17 since the latest window opened up back in August 2009. The Complete Genomics IPO makes it two in a row for DNA sequencing companies hitting the Nasdaq, with Pacific Biosciences (PACB) debuting just 10 trading days ago. Once again, however, we see the IPO price come in below the expected price: Complete Genomics priced its initial public offering of stock at Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Therapeutic Discovery Project Awards Provide Much Needed R&D Support

This morning, U.S. Treasury Secretary Timothy Geithner and HHS Secretary Kathleen Sebelius announced the awardees of the Therapeutic Discovery Project (TDP). We are running a few analytics on the recipient list and posting them here, along with links to relevant articles/blogs. Here is a primer: 5600 projects were submitted by ~3000 companies The maximum amount a project received was $244,479 78% of projects received the maximum amount Average project award was $217,108 72% of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

State of the Industry – From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final   From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IPO update: 28 IPOs, 24 on Deck

The number of IPOs slowed during the summer, but the queue has been filling nicely.  Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

1Q Cash Spending – Small Biotechs Still Spending Less

A comparison of cash spent on operations in the 1st quarter of 2010 vs the 1st quarters of 2009 and 2008 for small public biotechs shows a slowing in the precipitous drop seen over the last 2 years. However, the average small biotech is still spending less cash vs. 2008. When compared to 1Q08, the median cash flow from operations (CFO) in 1Q10 is down -40%. From 1Q09, median CFO is down -15%. See chart Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,